Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics.
Ratings
5 / 5
1 rating in the last 12 months
5
4
3
2
1
CEO
Dr. Samarth Kulkarni, PhD$4.9B
Market Cap • 25/07/20242013
(há 11 anos)
2016
(8 years ago)
NASDAQ
Listagem
Zug
458
N° de Empregados • 2022Valuation
Company FinancialsValuation Indicators
Valuation IndicatorsRetorno Histórico
CRSPSó no Premium...
Visualize o retorno de longo prazo das ações. Dividendos e outros eventos são considerados.